Alex Rogers, Executive Producer of the International Cannabis Business Conference, welcomes conference attendees and provides an overview of the conference schedule, including the panels and speakers that will be providing presentations and interviews.
Peter Homberg, a partner at Dentons Law Firm, will provide a thorough update regarding medical cannabis regulations and trends in Germany and Europe. Topics will include supply and demand in Germany and Europe, the German tender process regarding national cultivation of medical cannabis, cannabis exports/imports, price models, and potential harmonization of cannabis products within the EU.
Juergan Neumeyer of Cannabiswirtschaft will provide forward-looking insight and analysis of the German cannabis market and potential opportunities for cannabis entrepreneurs. Topics of focus will include domestic production, purchasing trends, and CBD. Mr. Neumeyer will also discuss the current state of cannabis politics in Germany.
Four years after the introduction of medical cannabis in Germany the market continues to develop rapidly, and pharmacies and patients often struggle to keep up due to regulatory shortcomings and unnecessary restrictions. Pharmacies continue to serve as the main distributors of medical cannabis in Germany. This panel will discuss Germany's current distribution model, ways to improve performance and supply, and how adult-use cannabis legalization may impact medical cannabis distribution.
The German medical cannabis market is one of the most valuable in the world - but unique challenges exist in navigating it successfully. Learn from the experts about what it takes to get your cannabis and products into the market and what leads to ongoing sales strategies that work.
The last two years have been a roller coaster ride for companies selling and developing CBD products – from the EU officially considering CBD as a narcotic to its highest court ruling that is exactly not a narcotic. Now the trend points to the liberalization of CBD regulation, which provides new opportunities for those companies but also opens up some new challenges. So where is the CBD market going? How does regulation still need to be reformed? How can providers of CBD products in pharmaceutical quality position themselves?
GMP homogenization is one of the largest issues facing the international medical and increasingly recreational market. In Europe, this issue is a front burner discussion, especially for those firms wishing to import into the German market - however it is a major issue everywhere. What are the problems seen by consultants and regulators as GMP regulations fail across borders?
What is "Novel Food" legislation and how are companies today in Europe and UK successfully finding a path to market within this stricture? What are the outstanding issues and how will this also affect the recreational THC market in Switzerland and Luxembourg as of next year?
Intellectual property law (trademarks/domain names/patents/copyrights/trade secrets) in the international cannabis industry have never been more important – and now more subject to lawsuits – than ever before. This panel will provide an overview of some of the key IP issues that cannabis operators and investors throughout the world are grappling with today.
Cannabis is entering the world of not only big pharma but the world of "bio-tech." As reform begins to unleash the ability of researchers to incorporate cannabinoids into their work, new discoveries are beginning to come fast and furious. An overview of what these are beginning to be.
The cannabis industry is now fully international. Biomass and products are being shipped globally. However, this is one of the most difficult and complicated parts of the entire industry. Learn from the experts what it takes to enter the international industry and what the biggest challenges still are in shipping cannabinoids across borders.
Add cannabis to emerging market dynamics and you have the recipe for economic development on steroids. Learn from the experts about what is going on in places like Poland, Greece and other emerging markets that are also on the brink of cannabis reform.
Doctor education has finally started to come to Europe - but what exactly does this mean? Beyond doctors however, what else is necessary from the industry to change perceptions of the plant and cannabinoid medicines - and at all levels - from national governments to municipal leaders, not to mention patients, insurers, and regulators?
Germany is at the brink of getting a new government, and the word is that it will most probably include the Green Party. Therefore, the perspectives for the legalization of recreational Cannabis use have never been better than now. But if so – then how? Most probably Germany would start with at least some kind of pilot projects like distribution via pharmacies and then end up in some highly regulated market. So, what are the role models for legalization German lawmakers look at? What can Cannabis companies expect? And how should they prepare for it?
CannaTech - Technology and cannabis are continuing to merge - in Europe this continues to be influenced by digital healthcare. What are some of the bigger issues across the European and British cannatech space as well as companies who are stepping up to meet the challenge
New cannabis rules, regulations, and laws are being crafted all over the globe right now, and in jurisdictions where the cannabis industry is already allowed to legally operate policy updates are being drafted and implemented on an ongoing basis. It is absolutely vital that the emerging cannabis industry has a voice in every policy discussion to ensure that the industry's concerns and needs are properly conveyed to policymakers and industry regulators. This panel of cannabis lobbying experts will discuss the importance of cannabis industry lobbying as well as provide guidance and tips regarding how to be an effective lobbyist.
Data and Analysis - If data is the new oil, what does this mean for the cannabis industry? Whose data, ultimately, is legitimate if not represents the market properly in a world where reform is still coming in fits and starts? What are the numbers to actually go by? Listen to analysts and others who talk about teasing the truth from the data that is available and understanding the big picture of where both the overall industry is as well as regional markets.
Cannabis marketing as well as media remains in an interesting place - although reform is clearly beginning to trickle through on the CBD side of the discussion. Learn from the experts about the new rules, what can be said (and not) where and most certainly when. When it is it ok to advertise and when? Is social media still off limits? And what are the regional differences in approaches region to region?
Please wait while you are redirected to the right page...